文献速递胰腺与胆道疾病消化内镜

置入腔壁贴合金属支架治疗胰腺液体积聚的真实世界影响:日本全国性研究

Real-world impact of implementing lumen-apposing metal stents for pancreatic fluid collections: a nationwide Japanese study.
PubMed 文献 · Gut · 2025-09-23

基于日本全国住院数据库2010至2023年550家医院5885例超声内镜引导下胰腺液体积聚治疗患者,比较腔壁贴合金属支架(LAMS)获批前后临床结局。LAMS后时代出血风险升高(调整OR 1.81,95%CI 1.55至2.13),总费用增加(调整系数2813美元,95%CI 1503至4122),抢救手术、院内死亡和住院时间无显著差异;验证队列出血风险调整OR 1.59(95%CI 0.86至2.95)未达统计学显著。

要点

  • LAMS后时代出血风险升高(调整OR 1.81,95%CI 1.55至2.13),塑料支架无此关联(调整OR 0.96,95%CI 0.74至1.26)。
  • LAMS后时代总费用增加(调整系数2813美元,95%CI 1503至4122),抢救手术、院内死亡和住院时间无显著差异(p>0.12)。
  • 按液体积聚类型分层,LAMS后时代与出血风险的关联在胰腺假性囊肿中似乎强于包裹性坏死(交互p=0.015)。

核心结论

  • LAMS置入与关键临床结局改善无关,但与出血风险升高和医疗费用增加相关。
  • 这些发现不支持在标准临床实践中对所有胰腺液体积聚的超声内镜引导治疗常规使用LAMS,但可将其限制于有明确适应证的包裹性坏死病例。

研究设计与样本

  • 使用全国住院数据库识别2010至2023年间550家医院5885例接受超声内镜引导下胰腺液体积聚治疗的患者。
  • 比较LAMS获批前与获批后时期(治疗时期)与临床结局的关联,采用多因素logistic回归和线性回归分别估计OR和系数。
  • 使用同期来自专科医院的多机构临床队列(n=618)验证发现。

主要发现

  • LAMS前时期3787例仅使用塑料支架治疗;2018年后2019至2023年治疗的2098例中LAMS使用率稳定在约50%。
  • 与LAMS前时期相比,LAMS后时期使用LAMS的患者出血风险更高(调整OR 1.81,95%CI 1.55至2.13),使用塑料支架者无此关联(调整OR 0.96,95%CI 0.74至1.26)。
  • 抢救手术率、院内死亡率和住院时间无显著差异(p>0.12)。
  • LAMS后时期与总费用增加相关(调整系数2813美元,95%CI 1503至4122)。
  • 按液体积聚类型分层,LAMS后时期与出血风险的关联在胰腺假性囊肿中似乎强于包裹性坏死(交互p=0.015);包裹性坏死患者在LAMS后时期住院时间更短、总费用更低(交互p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lumen-apposing metal stents (LAMSs) are increasingly used for the endoscopic management of pancreatic fluid collections (PFCs), including walled-off necrosis (WON) and pancreatic pseudocysts (PCs). OBJECTIVE: To evaluate the nationwide impact of implementing an LAMS (approved in Japan in 2018) on clinical outcomes in real-world settings. DESIGN: Using a nationwide inpatient database, we identified 5885 patients who underwent endoscopic ultrasound (EUS)-guided treatment for PFCs at 550 hospitals between 2010 and 2023. We examined the association between treatment period (pre-LAMS vs post-LAMS implementation) and clinical outcomes. Multivariable logistic and linear regression analyses were performed to estimate ORs and coefficients, respectively. Findings were validated using a multi-institutional clinical cohort (n=618) from specialty hospitals with more detailed clinical parameters with data collection during the same period. RESULTS: In the pre-LAMS period, 3787 cases were treated exclusively with plastic stents. After 2018, LAMS use stabilised at around 50% among 2098 cases treated between 2019 and 2023. Compared with the pre-LAMS period, patients treated during the post-LAMS period had a higher risk of bleeding with LAMS (adjusted OR, 1.81; 95% CI: 1.55 to 2.13), but not with plastic stents (adjusted OR, 0.96; 95% CI: 0.74 to 1.26). Rates of rescue surgery, in-hospital mortality and length of stay did not differ significantly (p>0.12). The post-LAMS period was associated with increased total costs (adjusted coefficient, US$2813; 95% CI: 1503 to 4122). In analyses stratified by PFC types (WON vs PC), the association of the post-LAMS period with bleeding risk appeared to be stronger for PCs than WON (pinteraction=0.015) and WON patients had a shorter length of stay and lower total costs in the post-LAMS period (pinteraction<0.001). In the validation cohort, the elevated bleeding risk with LAMS was confirmed (adjusted OR, 1.59; 95% CI: 0.86 to 2.95, vs pre-LAMS period), though not statistically significant. CONCLUSIONS: The implementation of LAMS was not associated with improved key clinical outcomes but was linked to a higher risk of bleeding and increased healthcare costs. These findings do not support the routine use of LAMS for EUS-guided treatment of all PFCs in standard clinical practice but may restrict it to WON cases with clear indications.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Hamada T, Michihata N, Saito T, et al. Real-world impact of implementing lumen-apposing metal stents for pancreatic fluid collections: a nationwide Japanese study. Gut. 2025. PMID: 40738742. doi:10.1136/gutjnl-2025-335067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。